Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 8Breast Neoplasms 7Polycythemia Vera 5Venous Thromboembolism 3Melanoma 3Colonic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Tobacco Use Disorder 2Thrombocythemia, Essential 2Smoking Cessation 2Rectal Neoplasms 2Prostatic Neoplasms 2Neoplastic Cells, Circulating 2Neoplasms 2Neoplasm Metastasis 2Myeloproliferative Disorders 2Multiple Myeloma 2Lung Neoplasms 2Barrett Esophagus 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Tuberous Sclerosis 1Thromboembolism 1Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Seizures 1Salivary Gland Neoplasms 1Recurrence 1Primary Myelofibrosis 1Precancerous Conditions 1

Interventions

Memantine 2lithium sulfate 1lime 1fasudil 1XENP 1595 1Ramipril 1Methylphenidate 1Lithium 1Infliximab 1Ibuprofen 1Exercise 1Cannabidiol 1Behavior Therapy 1Aspirin 1Ashwagandha 1Anticonvulsants 17-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Cognitive Dysfunction × Aspirin × Clear all
NCT03356769 2020-06-09

Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex

Peking Union Medical College Hospital

Phase 2 Unknown
98 enrolled

Epilepsy, Seizures, Tuberous Sclerosis, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡